1044598-91-5

Usage

Uses

Used in Pharmaceutical Industry:
4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]benzoic Acid is used as an intermediate in the production of cell death regulators and apoptosis promoters. Its role in the synthesis of these biologically active molecules is crucial for developing new therapeutic agents that can modulate cellular processes and combat diseases associated with uncontrolled cell growth or resistance to apoptosis.
As an intermediate, 4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]benzoic Acid contributes to the development of pharmaceuticals targeting various diseases, including cancer, where the regulation of cell death is a critical aspect of treatment. By promoting apoptosis, these regulators can help eliminate cancerous cells and potentially reduce the severity or progression of the disease.

Upstream product

• 1044598-93-7 tert-butyl 4-(4-{[2-(4-chlorophenyl)-2-hydroxy-5,5-dimethylcyclohexyl]methyl}piperazin-1-yl)benzoate 
• 80518-57-6 ethyl 4-(piperazin-1-yl)benzoate 
• 1065604-58-1 ethyl 4-(4-((2-bromo-5,5-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)benzoate 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 1027345-22-7 6-(bromomethyl)-4'-chloro-4,4-dimethyl-2,3,4,5-tetrahydro-1,1'-biphenyl 
• 1027345-21-6 (4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methanol 
• 1202186-71-7 4-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1-biphenyl]-2-carbaldehyde 
• 1065604-70-7 ethyl 4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl) benzoate 

Downstream Products

• 923564-51-6 navitoclax 
• 852811-25-7 (R)-4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(4-(4-(dimethylamino)-1-(phenylthio)butan-2-ylamino)-3-nitrophenylsulfonyl)benzamide 

Relevant academic research and scientific papers

INHIBITING B-CELL LYMPHOMA 2 (BCL-2) AND RELATED PROTEINS

Novel compounds inhibiting anti-apoptosis proteins B-cell lymphoma 2 (Bcl-2) and Bcl-XL include compounds of formula (I) and formula (II) disclosed herein, as well as liposome compositions comprising Bcl-2 inhibitor compounds. These compositions are usefu

ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS

Compounds represented by Formula (I) and (II) and salts thereof are described herein. The compounds or salts of Formula (I) and (II) may be used to treat senescence-associated diseases and disorders.

Profiling small molecule inhibitors against helix-receptor interactions: The Bcl-2 family inhibitor BH3I-1 potently inhibits p53/hDM2

We validate a practical methodology for the rapid profiling of small molecule inhibitors of protein-protein interactions. We find that a well known BH3 family inhibitor can potently inhibit the p53/hDM2 interaction.

Processes To Make Apoptosis Promoters

Processes to make compounds, including N-acylsulfonamide apoptosis promoters are disclosed.

An efficient synthesis of ABT-263, a novel inhibitor of antiapoptotic Bcl-2 proteins

ABT-263, a newly developed Bcl-2 inhibitor, was efficiently synthesized. The key intermediates 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enyl] methyl}piperazin-1-yl)benzoic acid and 4-fluoro-3-[(trifluoromethyl)sulfonyl] benzenesulfonamide were eff

Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins

Overexpression of prosurvival proteins such as Bcl-2 and Bcl-XL has been correlated with tumorigenesis and resistance to chemotherapy, and thus, the development of antagonists of these proteins may provide a novel means for the treatment of can